摘要
目的:观察吉非替尼(Gefitinib,ZD1839)治疗非小细胞肺癌的疗效及毒副作用。方法:自2005年2月-2006年2月用吉非替尼250mg,每日口服,治疗失去手术机会及放化疗无效的非小细胞肺癌患者32例。结果:32例患者均可评价,获得CR2例(6.25%),PR5例(15.63%),有效患者共7例(21.88%);SD15例(46.88%),其中持续时间≥24周者14例;故临床获益率为65.63%[(2+5+14)/32];PD10例(31.25%)。与药物相关的不良反应依次为:皮疹15例(46.88%),恶心8例(25%),腹泻7例(21.88%),皮肤干燥4例(12.5%),乏力2例(6.25%),其它如发热、口腔溃疡及关节痛等副反应发生率均<5%。实验室指标未发现异常。结论:吉非替尼治疗晚期非小细胞肺癌有效,毒副反应少,患者耐受性好,值得推广应用。
Objective：To Observe the efficacy and toxic and side effect of Gerfitinib （ZD1839） in treatinent of non - small cell lung cancer. Methods： From Feb. 2005 to Feb. 2006, oral Gefitinib in dose of 250mg daily were given in 32 patients with advanced non-small cell lung cancer. Results： 2 of 32 patients （6.25%）had complete response （CR）, 5 （15.63 % ） Partial response （PR）. 7 of 32 patients （21.88 % ） was effective to the medicine. The condition in 15 patients wasstable including 14 ones with stable duration more than or equal to 24 Weeks. So the effective rate was 65.63%. 10 Patients had progressive diseases. The adverse reaction induced by medication was skin rash in 15 patients, nausea in 8 ones, diarrhea in 7 ones, Xerosis eutis in 4 ones and fatigue in 2 ones. Other adverse reaction included fever, dental ulcer and athralgia （ （ 5 % ）, There was no abnormal laboratory index. Conclusion： Gefitinib is effective in treatment of advanced non - small cell lung cancer, with less toxi C and side effect and better tolerance. The medication should be reeommeded.
出处
《内蒙古医学杂志》
2007年第4期439-441,共3页
Inner Mongolia Medical Journal
